middle.news
How Aroa Biosurgery’s Symphony and Myriad Are Shaping FY26 Growth
8:54am on Tuesday 3rd of February, 2026 AEDT
•
Healthcare
Read Story
How Aroa Biosurgery’s Symphony and Myriad Are Shaping FY26 Growth
8:54am on Tuesday 3rd of February, 2026 AEDT
Key Points
US CMS sets single outpatient skin substitute reimbursement at US$127.14/cm²
Symphony Randomised Control Trial completed; publication expected FY27
Myriad trauma study shows rapid wound coverage with low complications
FY26 revenue guidance reaffirmed at NZ$92-100 million, EBITDA NZ$5-8 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aroa Biosurgery (ASX:ARX)
OPEN ARTICLE